2George A J, Holsinger RM, McLean CA, et al. APP intracellular domain is increased and soluble Aβ is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis, 2004,16 : 124-132.
3Hutter-Paier B, Huttunen H J, Pugielli L, et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer disease. Neuron, 2004, 44: 227- 238.
4Postina R,Schroeder A, Dewaehler I, et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease's mouse model. J Clin Invest, 2004,113 : 1456-1464.
5Pedrini S,Carter TL,Prendergast G, et al. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med, 2005,2: 69-78.
6Zhou Y, Su Y, Li B, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting Rho. Science.2003,302:1215-1217.
7Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov, 2005,4:387-398.
8Tang BL. Alzheimer's disease: channeling APP to non-amyloidogenic processing. Biochem Biophys Res Commun, 2005, 331:375-378.
9Yoon SY, Choi JE, Yoon JH, et al. BACE inhibitor reduces APP-β-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration. Neurobiology of Disease, 2006,22 : 435-444.
1Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 1999,286 : 735 -741.
2Farzan M, Schnitzler CE, Vasilieva N. BACE2, a betasecretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein.Proc Natl Acad Sci USA,2000,97 : 9712 -9717.
3Yan R, Munzner JB, Shuck ME, et al. BACE2 functions as an alternative secretase in cells. J Biol Chem, 2001,276 :34019 - 34027.
4Li YM, Xu M, Lai MT, et al. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1. Nature,2000,405 : 689 -694.
5Herreman A, Semeels L, Annaert W, et al. Total inactivation of γ-secretase activity in presenilin-deficient embryonic stem cells. Nat Cell Biol,2000,2 : 461 -462.
6Yu G,Nishimura M, Arawaka S, et ai. Nicastrin modulates presenilin-mediated Notch/GLP-1 signal transduction and beta-APP processing. Nature,2000,407 : 48 - 54.
7Francis B,McGrath G,Zhang J,ct al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation.Dev Ce11,2002,3 : 85 -97.
8Roberds SL,Anderson J,Basi G,et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: imphcations for Alzheimer's disease therapeutics.Hum Mol Genet, 2001,10 : 1317 -1324.
9Citron M. Secretases as targets for the treatment of Alzheimer's disease. Molecular Medicine Today, 2000,6 : 392 -397.
10Marina VF, Larisa K, Christian G. Specific gap junction enhances the neuronal vulnerability to brain traumatic injury[J]. J Neurosci, 2002,22: 644-653.
3Funamoto S, Morishima Kawashima M, Tanimura Y, et al. Truncated carboxyl terminal fragments of 18- amyloid precursor protein are processed to amyloid beta protein 40 and 42. Biochemistry, 2004, 43: 13 532-13 540.
4Deshpande A, Mina E, Glabe C, et al. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons J. Neurosci, 2006,26:6011- 6018.
5Adlard PA,Cherny RA, Finkelstein DI, et al. Rapid restoration of cognition in Alzheimer' s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron, 2008,59: 43-55.
6Ida N, Hartmann T, Pantel J, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem, 1996, 271: 22 908-22 914.
7Gandy SE, Bhasin R, Ramabhadran TV, et al. Alzheimer beta/A4-amyloid precursor protein: evidence for pulative amyloidogenic fragment. J Neurochem,1992,8,383- 386.
8Liu L,Guo XE, Zhou YQ, et al. Prevalence of dementia in China. Dement Geriator Cogn Disord, 2003,15:226-230.
9Pietrzik C.Behl C. Concepts for the treatment of Alzheimer' s disease: molecular mechanisms and clinical application. Int J Exp Pathol, 2005, 86: 173-185.
10Ohyagi Y. Molecular pathology and therapeutics in Alzheimer' s disease: amyloid beta-protein as a therapeutic target. Fukuoka Igaku Zasshi, 2006,97: 261-268.
